Estramustine phosphate sodium, an antineoplastic agent, is an off-white powder readily soluble in water. EMCYT Capsules are white and opaque, each containing estramustine phosphate sodium as the disodium salt monohydrate equivalent to 140 mg estramustine phosphate, for oral administration. Each capsule also contains magnesium stearate, silicon dioxide, sodium lauryl sulfate, and talc. Gelatin capsule shells contain the following pigment: titanium dioxide.
EMCYT Capsules are indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.
Media Articles Related to Emcyt (Estramustine)
Debate Over Chemotherapy for Nonmetastatic Prostate Cancer
Source: Medscape Hematology-Oncology Headlines [2016.11.28]
Two sets of experts debate whether chemotherapy should be considered for men with nonmetastatic castration-resistant prostate cancer.
Medscape Medical News
Why are black men missing from prostate cancer research?
Source: Prostate / Prostate Cancer News From Medical News Today [2016.11.25]
Black men are three times more likely to develop prostate cancer than other demographics, yet black men are consistently underrepresented in research studies, say researchers from King's College...
Computer modeling could lead to new method for detecting, managing prostate cancer
Source: Medical Devices / Diagnostics News From Medical News Today [2016.11.23]
New research coauthored by Brigham Young University researchers may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer.
How to Improve Your Sex Life After Prostate Cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2016.11.21]
What is the prostate gland and how can prostate cancer affect sexual behavior? Learn how to manage your sex life after prostate cancer and its treatment.
Advanced Prostate Cancer: Symptoms, Treatment, and Outlook
Source: Prostate / Prostate Cancer News From Medical News Today [2016.11.18]
Learn all about advanced prostate cancer, how it develops, and the symptoms it causes. This article also looks at survival rates for this condition.
Published Studies Related to Emcyt (Estramustine)
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. [2010.07]
Personalized peptide vaccination (PPV) combined with chemotherapy could be a novel approach for many cancer patients. In this randomized study, we evaluated the anti-tumor effect and safety of PPV plus low-dose estramustine phosphate (EMP) as compared to standard-dose EMP for HLA-A2- or -A24-positive patients with castration resistant prostate cancer...
Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. [2010.03]
OBJECTIVE: The objective of this study is to assess the safety and efficacy of a treatment regimen comprising neoadjuvant conventional androgen deprivation therapy (ADT) plus estramustine phosphate (EMP) combined with three-dimensional conformal radiotherapy (3D-CRT) for patients with intermediate- to high-risk prostate cancer... CONCLUSIONS: The present results indicate that the combination of neoadjuvant ADT plus EMP combined with 3D-CRT sustains freedom from PSA relapse in patients with intermediate- to high-risk prostate cancer. However, this regimen is insufficient for preventing biochemical failure, and an additional intervention such as adjuvant ADT, radiation dose escalation, or both, is required, especially for patients with a pretreatment PSA level of more than 20 ng/ml and high-grade cancer.
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. [2010.02.24]
BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC)... CONCLUSIONS: Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC. Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted. The feasibility of measuring Bcl-2 protein in a cooperative group setting is hypothesis generating and supports further study as a marker for Bcl-2 targeted therapy. TRIAL REGISTRATION: Clinical Trials Registration number: CDR0000067865.
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. [2009.03.01]
CONCLUSION: TEE was associated with significantly increased toxicity during treatment. The toxicity profiles did not differ at 2 and 3 years after therapy. Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. [2008.11.10]
PURPOSE: To assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer... CONCLUSION: The addition of estramustine to weekly D does not provide any clinically relevant advantage. Both regimens are well tolerated, although the toxicity profile favors D without estramustine.
Clinical Trials Related to Emcyt (Estramustine)
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer [Completed]
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy
consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus
doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma [Completed]
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer [Completed]
we propose to randomize patients with hormone resistant prostate cancer between
docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The
principal endpoint will be the efficacy in term of PSA response.
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer [Recruiting]
The purpose of this clinical trial is to find out the effect of epirubicin with estramustine
phosphate and celecoxib on PSA and objective response in patients with hormone resistant
prostate cancer as well as evaluating the toxicity, quality of life of this combination.
Celecoxib is an FDA approved drug to treat arthritis. Epirubicin, alone or with
estramustine phosphate has been used in the treatment of hormone resistant prostate cancer.
These drugs have demonstrated evidences of tumor blood vessel suppression and combination
of these three drugs could possibly arrest further tumor growth or even make the tumor
decrease in size.
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer [Completed]
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and
Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the
treatment of hormone refractory prostate cancer. The investigators will determine the
tolerable dose of (oral) vinorelbine in combination with (oral) estramustine, and evaluate
the efficacy of this treatment for patients with hormone-refractory prostate cancer.